Stonebridge Capital Advisors’s Novo Nordisk NVO Stock Holding History

Stonebridge Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,038	Closed	-$94.4K	–	624
2023 Q3	$94.4K	Sell	1,038 -10	-1%	-$881	0.01%	278
2023 Q2	$84.8K	Buy	1,048 +550	+110%	+$44.9K	0.01%	286
2023 Q1	$39.6K	Buy	498 +110	+28%	+$7.8K	﹤0.01%	394
2022 Q4	$26.3K	Buy	388 +10	+3%	+$586	﹤0.01%	447
2022 Q3	$19K	Buy	378 +72	+24%	+$3.86K	﹤0.01%	480
2022 Q2	$17K	Hold	306	–	–	﹤0.01%	518
2022 Q1	$17K	Hold	306	–	–	﹤0.01%	559
2021 Q4	$17K	Hold	306	–	–	﹤0.01%	539
2021 Q3	$15K	Sell	306 -306	-50%	-$14.8K	﹤0.01%	552
2021 Q2	$23K	Buy	612 +306	+100%	+$11.9K	﹤0.01%	593
2021 Q1	$10K	Buy	+306	New	+$10.9K	﹤0.01%	635
2020 Q3	–	Sell	-250	Closed	-$8K	–	530
2020 Q2	$8K	Hold	250	–	–	﹤0.01%	522
2020 Q1	$8K	Hold	250	–	–	﹤0.01%	508
2019 Q4	$7K	Sell	250 -92	-27%	-$2.55K	﹤0.01%	599
2019 Q3	$9K	Hold	342	–	–	﹤0.01%	565
2019 Q2	$9K	Buy	+342	New	+$8.45K	﹤0.01%	591

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Stonebridge Capital Advisors's NVO Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Novo Nordisk (NVO) in Q4 2023, closing a stake of 1,038 shares — an estimated $94.4K sold.

Stonebridge Capital Advisors first reported a position in NVO in Q2 2019 and held it in 16 quarters. The position peaked at $94.4K in Q3 2023. 1,511 funds tracked by Wall St. Rank hold NVO as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Novo Nordisk position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 1,038 Novo Nordisk shares in Q4 2023, an estimated $94.4K.
Stonebridge Capital Advisors first reported a position in Novo Nordisk in Q2 2019 and held it in 16 quarters.
Stonebridge Capital Advisors's Novo Nordisk position peaked at $94.4K in Q3 2023.
1,511 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.